Original Research
Accepted on 28 Apr 2025
Cost-effectiveness analysis of Toripalimab regimen for extensive-stage small-cell lung cancer in China and America
in Cancer Immunity and Immunotherapy
- 140 views
Original Research
Accepted on 28 Apr 2025
in Cancer Immunity and Immunotherapy
Original Research
Accepted on 28 Apr 2025
in Cancer Immunity and Immunotherapy
Case Report
Accepted on 28 Apr 2025
in Cancer Immunity and Immunotherapy
Original Research
Accepted on 28 Apr 2025
in Cancer Immunity and Immunotherapy
Original Research
Accepted on 28 Apr 2025
in Cancer Immunity and Immunotherapy
Original Research
Accepted on 28 Apr 2025
in Cancer Immunity and Immunotherapy
Review
Accepted on 28 Apr 2025
in Inflammation
Original Research
Accepted on 28 Apr 2025
in Cancer Immunity and Immunotherapy
Review
Accepted on 28 Apr 2025
in Molecular Innate Immunity
Original Research
Accepted on 28 Apr 2025
in Cancer Immunity and Immunotherapy
Original Research
Accepted on 28 Apr 2025
in Inflammation
Case Report
Accepted on 28 Apr 2025
in Inflammation
Editorial
Accepted on 28 Apr 2025
in Inflammation
Original Research
Accepted on 28 Apr 2025
in Inflammation
Review
Published on 28 Apr 2025
in Nutritional Immunology
Original Research
Published on 28 Apr 2025
in Comparative Immunology